Background: Alkaline phosphatase is a glycoprotein that catalyzes two kinds of chemical reactions: hydrolysis of phosphorus ester breaking P-O bonds and phospho-transfer reactions in which phosphoric group is transferred to an acceptor molecule. In the human body, ALP exists in multiple molecular forms whose heterogeneity is partly due to genetic factors and partly to posttranslational modifications. The aim was to evaluate a total ALP activity and its isoforms in cancer patients with bone and liver metastasis in comparison to healthy controls. Methods: Human serum was collected from 20 healthy individuals, and 20 cancer patients with bone and liver metastases, with metastases confirmed by ultrasound, computerized tomography and a radiology scan. Determination of ALP was done by the endpoint spectrophotometric method. Isoenzymes were determined by heat inactivation method. Results: In cancer patients, the total ALP activity was significantly higher (p< 0.05) compared to healthy controls. In the sera of cancer patients with liver metastases, the remaining ALP activity was two-fold higher in comparison to bone metastases. Conclusion: Determination of ALP isoenzymes is important but a correct clinical interpretation in the context of other analyses is vital for a proper diagnosis of a disease. [Projekat Ministarstva nauke Republike Srbije, br.175056
-Objective: The aim of our study was to evaluate the effects of low doses of clozapine in flexible regime in comparison with haloperidol and chlorpromazine in long term. Method: The naturalistic study was prospective, active-controlled with 325 adult outpatients of both genders (140 females), with mean year age of 34.8 (range 21-57), suffering from chronic schizophrenia. The first onset of illness was at the mean of 27.9 years (range 17-38), and subjects had the mean year age of 4.1±0.5 previous relapses. The patients were allocated to receive haloperidol (105 subjects, dose range 2-15 mg), chlorpromazine (n=105, 100-400 mg) or clozapine (n=115, 75-600 mg). The scores of psychometric instruments (GWB, PANSS, CGI) were regularly assessed during 5 year period. Results: The sixty-six responders were included in per-protocol analysis: 12, 10 and 16 with positive and 7, 6 and 15 with negative schizophrenic syndrome in haloperidol, chlorpromazine and clozapine group, respectively. The statistically significant differences in all psychometric scores was found, for both schizophrenic syndromes, favoring clozapine. The distribution of eighteen different types of adverse events, which we noted, were significantly different among treatment groups (χ 2 =315.7, df=34, p<0.001). Clozapine was safer and had fewer adverse effects (average of 0.9 adverse events per patient) than haloperidol (2.7) and chlorpromazine (3.2). Conclusions: Clozapine, in low doses of flexible regime, in long term (five years) showed better effectiveness in chronic schizophrenics with positive and negative symptoms than typical antipsychotics.Key WordS: schizophrenia, antipsychotics drugs, long-term outcomes, clinical practice. Eficácia da clozapina, haloperidol e clorpromazina na esquizofrenia em um período de cinco anosResumo -Objetivo: o propósito deste estudo foi avaliar os efeitos de baixas doses de clozapina em regime flexível comparando com o uso de haloperidol e clorpromazina por período de 5 anos. Método: Um estudo prospectivo naturalístico, ativo-controlado foi realizado com 325 pacientes com idade média de 34,8 (variância 21-57). Todos com diagnóstico de esquizofrenia. No primeiro surto da doença os pacientes apresentavam idade média de 27,9 anos (variância 17-38) e os surtos subsequentes apareceram em média 4,1±0,5 anos após. os pacientes foram orientados a receberem haloperidol (105 pacientes com dose entre 2 e 15 mg), clorpromazina (105 pacientes com dose entre 100 e 400 mg) e clozapina (115 pacientes com dose entre 75 e 600 mg). os instrumentos psicométricos utilizados (GWB, PANSS e CGI) foram regularmente empregados durante os 5 anos do estudo. Resultados: os 66 pacientes respondedores ao tratamento foram incluídos no protocolo de análise: 12, 10 e 16 apresentavam síndrome esquizofrênica positiva e 7, 6 e 15 síndrome negativa esquizofrênica com haloperidol, clorpromazina e clozapina, respectivamente. diferenças estatísticas significantes foram observadas em todas as avaliações psicométricas em ambas síndromes esquizofrênicas f...
Data about mortality from malignant tumors of endometrium were analyzed in the Belgrade area during the period 1975-2000. The obtained results showed that the average percentage of endometrial cancer in mortality structure from all the cancers of female population was 2.65%. During the observed 26-years period, malignant tumors of endometrium constituted 17.38% of all the tumors of gynecological localization. The standardized mortality rate in 1975 (population worldwide used as a standard) 7.06/100,000 population, while in 2000 it was 1.78/100,000 population, respectively, which showed almost fourfold mortality decline during the observed period (y=4.72-0.16x). A trend of declining risk of dying from endometrial cancer was present in all the age groups. The obtained results indicated that in the observed period the average mortality rates ranged from 0.14/100,000 population in females aged up to 34 years (y=0.30-0.01x), and reached the highest value in females aged 65-74 years (14.57/100,000; y=23.43-0.66x), and 75 years of age and over (19.62/100,000; y=31.17-0.85x).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.